Currently, the “AD CSF biomarker profile” is widely recognized and is characterized by increased concentrations of CSF tau proteins (total Tau protein and phosphorylated Tau protein), along with decreased concentration of CSF amyloid beta peptide with 42 amino acids (Aβ42) [30]. This evidence concerns the gene MAPT and Alzheimer disease.